Edwards Lifesciences (NYSE:EW) Upgraded at Barclays

Barclays upgraded shares of Edwards Lifesciences (NYSE:EW) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks reports.

EW has been the topic of several other reports. UBS Group initiated coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 price target on the stock. JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Mizuho lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Finally, Evercore reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Up 1.2%

Shares of EW stock opened at $85.27 on Wednesday. Edwards Lifesciences has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $49.10 billion, a PE ratio of 49.00, a price-to-earnings-growth ratio of 2.21 and a beta of 0.87. The stock has a 50 day moving average of $88.72 and a 200-day moving average of $86.16.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts predict that Edwards Lifesciences will post 3.00 EPS for the current year.

Insider Activity

In related news, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,428,912.10. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 5,045 shares of company stock worth $451,596. Company insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter valued at about $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter valued at about $26,000. Pin Oak Investment Advisors Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at about $26,000. Finally, GK Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at about $26,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.